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Abstract We have compared responses in platelets stimulated
with the particulate materials, Intralipid (liposome-suspension)
and a potential contrast medium IEEC (1P-(ethyloxycarbonyl-
oxy)-ethyl-5-acetyl-amino-3-(N-methyl-acetylamino)-2,4,6-tri-
iodo-benzenecarboxylate coated with human serum albumin),
with and without forskolin and inhibitors of autocrine stimulation
(IAS: an ADP-removing system of creatine phosphate/creatine
phosphokinase; RGDS to prevent fibrinogen/fibronectin binding
to GPIIb/IIIa; SQ 29.548 as a TXA2 receptor antagonist ;
cyproheptadine as a serotonin receptor antagonist ; BN 52021 as
a platelet-activating factor receptor antagonist). The pattern of
tyrosine-phosphorylated proteins, phosphorylation of initial
lipids and phosphorylation of pleckstrin (P47) were used as
markers for early signal transducing responses, while secretion of
ADP+ATP and L-N-acetyl-glycosaminidase were used as final
responses. Intralipid showed no platelet activation except for
some weak tyrosine protein phosphorylation that was inhibited
by elevated cAMP. IEEC induced strong platelet activation that
was partly inhibited by increased levels of cAMP and IAS. The
inhibition of elevated cAMP seemed to be due to removal of the
G protein-mediated activation from secreted autocrine stimula-
tors either by IAS or forskolin. The remaining activity is a pure
effect from IEEC which is not affected by elevated cAMP.
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1. Introduction
Particulate contrast media of di¡erent sizes and materials
have been developed to be selectively absorbed by liver and
spleen in order to detect tumors in these organs [1^4]. How-
ever, platelets are activated by most foreign surfaces, and
recognition of arti¢cial (e.g. glass, gas-bubbles) and natural
(collagen ¢brils, bacteria, viruses and other microorganisms)
particles as foreign materials, most often leads to platelet ac-
tivation by ill-de¢ned mechanisms. The IEEC contrast par-
ticles ful¢l most of the criteria for a particulate contrast me-
dium and consist of solid, iodinated (51.2 percent w/w)
particles (1.28^3.57 Wm in diameter) with human serum albu-
min coating to avoid particle aggregation [2,5].
In preliminary experiments by us IEEC was shown to ag-
gregate human platelets, both in whole blood, PRP and GFP.
The aim of this study was to elucidate the reaction mecha-
nisms induced in human platelets by IEEC in comparison to
Intralipid by measuring both early responses like protein ty-
rosine phosphorylation, incorporation of 32P into the lipids of
the polyphosphoinositide cycle (PI, PIP, PIP2 and PA), phos-
phorylation of pleckstrin (P47) and ¢nal responses like secre-
tion from the dense granules and lysosomes.
Agonist-activated platelets liberate and produce substances
that are potent platelet activators: ADP, ¢brinogen, ¢bronec-
tin, serotonin, platelet-activating factor, TXA2 and PGH2.
These platelet-made agonists potentiate the e¡ects of the pri-
mary agonist in a synergistic manner [6,7]. Furthermore, close
cell contact produced by platelet aggregation will also act as a
potentiating stimulus [8^10]. To study the pure e¡ects of the
particles themselves, the experiments have been performed in
the presence of inhibitors of autocrine stimulation (IAS): (1)
creatine phosphate/creatine phosphokinase (CP/CPK) to re-
move ADP, (2) RGDS to prevent ¢brinogen/¢bronectin bind-
ing and thereby close cell contact, (3) SQ 29.548 as a TXA2
receptor antagonist, (4) cyproheptadine as a serotonin recep-
tor antagonist and (5) BN 52021 as a platelet-activating factor
receptor antagonist. Common for these antagonists is that
they act from the outside of the platelet, thus preventing the
secreted products to bind to their receptors or to remove
them, as in the case of ADP.
A major di¡erence between the particulate agonist collagen
and the soluble agonist thrombin is that collagen causes a
massive protein tyrosine phosphorylation while thrombin
does not [11,12]. Thus, protein tyrosine phosphorylation
may be mandatory steps in the early signal transduction em-
ployed by the particulate agonists per se, and this has been
studied in detail for IEEC and Intralipid in the present com-
munication. Furthermore, collagen-induced responses seem to
be una¡ected by increased [cAMP]i, in contrast to thrombin
[12^14]. We wanted to determine whether IEEC and Intralipid
showed the same properties as collagen by the above-men-
tioned criteria. We have used forskolin, which stimulates the
catalytic subunit of adenylyl cyclase directly to increase
[cAMP]i, thus bypassing the receptor-G protein level [15,16].
Thus, gel-¢ltered, human platelets were treated with IEEC
and Intralipid both in the absence and presence of IAS and
forskolin to elucidate the activation mechanisms induced
under stimulating and inhibiting conditions.
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2. Materials and methods
2.1. Materials
[32P]orthophosphate (carrier-free, Code PBS-11) was obtained from
Amersham, Bucks, UK. Bovine serum albumin, fraction V (pH 7,
lyophilized) was from ICN Biomedicals, Inc., Aurora, OH, USA.
IEEC (1P-(ethyloxycarbonyloxy)-ethyl-5-acetyl-amino-3-(N-methyl-
acetylamino)-2,4,6-triiodo-benzenecarboxylate) was from Nycomed
Imaging A/S, Oslo, Norway, while Intralipid was from Kabi Pharma-
cia AB, Stockholm, Sweden. Creatine phosphate (CP), creatine phos-
phokinase (CPK), cyproheptadine and forskolin were purchased from
Sigma, St. Louis, MO, USA, SQ 29.548 from Research Biochemicals
International, MA, USA, RGDS from Calbiochem-Novabiochem
Intl., La Jolla, CA, USA, BN 52021 from Biomol Research Labora-
tories, PA, USA. ATP monitoring reagent (a ¢re£y luciferin/luciferase
kit) was from Bio Orbit Oy, Turku, Finland. CP, CPK, RGDS and
cyproheptadine were dissolved in 0.15 M NaCl, while SQ 29.548 and
BN 52021 were dissolved in dimethylsulfoxide (DMSO). Stock solu-
tion of forskolin was dissolved in 96% ethanol and stored at 320‡C.
Stock solutions of IEEC, Intralipid, thrombin and the inhibitors of
autocrine activation were diluted with their appropriate solvents to
the desired concentrations just before use, and discarded after use.
2.2. Preparation of [32P]Pi-labelled gel-¢ltered platelets
Fresh blood (450 ml), drawn into 72 ml of ACD (71 mM citric acid,
85 mM Na3 citrate, 111 mM dextrose), was obtained at the Blood
Bank, Haukeland Sykehus from healthy human volunteers who de-
nied to have taken any medications 10 days prior to blood with-
drawal. Further procedure, involving preparation of [32P]Pi-labelled,
gel-¢ltered platelets, is described elsewhere [17].
2.3. Incubations
The procedure used is described elsewhere [12]. The concentrations
of the di¡erent inhibitors in the IAS solution are given in the text to
Fig. 1. IEEC or Intralipid were added to the incubates at ¢nal con-
centrations of 10 mg I/ml and 10 mg/ml respectively, and incubated
for 3 min at 37‡C with stirring before aliquots were taken out for
analyses.
2.4. Extraction, thin layer chromatography and determination of
radioactivity of phospholipids
This was performed as described by Tysnes et al. [18] with some few
modi¢cations [17].
2.5. Tyrosine phosphorylation
The procedure used previously [11] was used without modi¢cations.
In short, proteins were detected by Western analysis of whole cell
lysates using the phosphotyrosine speci¢c antibody 4G10 and a sec-
ondary IgG antibody conjugated to HRP and visualized by ECL.
2.6. Phosphorylation of pleckstrin
IEEC caused marked [32P]phosphorylation of myosin light chain
(Mr = 20 kDa) and pleckstrin (Mr = 47 kDa) in the platelets (results
not shown). However, elevation of intracellular cAMP by treatment
of GFP with forskolin resulted in the appearance of many phospho-
rylated proteins with Mr in the 20^28 kDa range, as found by Haslam
et al. [19], which unabled us to determine the degree of myosin light
chain phosphorylation. Only pleckstrin phosphorylation was therefore
determined, as described elsewhere [12].
2.7. Measurement of secreted ADP+ATP and
L-N-acetylglycosaminidase
The procedures utilizing ¢re£y luminescence for ADP+ATP and
4-methylumbelliferyl-N-acetyl-L-D-glucosaminide as substrate for
L-N-acetylglycosaminidases are described elsewhere [11].
2.8. Statistics
Statistical comparisons were made using Student’s paired two-tailed
t-test.
(***) 0.019P9 0.02, (**) 0.029P9 0.05 and (*) Ps 0.05.
3. Results and discussion
3.1. Protein tyrosine phosphorylation
Fig. 1 (upper part) shows a comparison between IEEC- and
Intralipid-induced protein tyrosine phosphorylation with re-
FEBS 20914 8-10-98
Fig. 1. Stimulation of protein tyrosine phosphorylation and [32P]pleckstrin by Intralipid and IEEC, and the selective inhibition by forskolin
and inhibitors of autocrine stimulation. NaCl (150 mM), Intralipid (10 mg/ml) and IEEC (10 mg I/ml) were added to 1 ml of GFP that had
been treated with either solvent, inhibitors of autocrine stimulation (IAS). The volumes added and ¢nal concentrations in GFP of each auto-
crine inhibitor were: 20 Wl of the ADP-removing system CP/CPK (5 mM/10 U/ml), 5 Wl of the serotonin antagonist cyproheptadine (2 WM),
3 Wl of the thromboxane A2 receptor antagonist SQ 29.548 (150 WM), 5 Wl of the platelet-activating factor (PAF) antagonist BN 52021
(150 WM) and 5 Wl of the ¢brinogen/¢bronectin inhibitor RGDS (150 WM), forskolin (1 WM) or both forskolin and IAS. [DMSO] in the GFP
was 0.77%. The IAS were preincubated in the [32P]Pi-labelled gel-¢ltered platelets for 8 min at 37‡C under non-stirring conditions, after which
the particles were added and the mixtures incubated for another 3 min under stirring conditions before samples were taken out for analysis of
tyrosine phosphorylation. The ¢gure shows a Western immunoblot of proteins separated by SDS-PAGE, probed with 4G10 mouse anti-phos-
photyrosine antibody and then as a secondary antibody probed with HRP-conjugated anti-mouse IgG and developed by an ECL method as de-
scribed in Section 2. Lysate from 6U106 platelets were loaded in each lane. The results shown are representative for three independent experi-
ments with duplicate samples. Table 1 contains the determinations of the total tyrosine phosphorylation obtained by scanning and are based
on six separate immunoblots.
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spect to the inhibition by forskolin and IAS. NaCl (150 mM),
IEEC (10 mg I/ml) and Intralipid (10 mg/ml) were added to
GFP that had been treated with either solvent, IAS alone,
forskolin alone (1 WM) or both forskolin and IAS. GFP was
incubated for 3 min with stirring before samples were taken
out for determination of tyrosine phosphorylation. The blots
were exposed optimally for the IEEC e¡ect and are somewhat
underexposed for the control samples, where proteins with
molecular weight (MW) of about 33, 35, 55, 60 (src), 68
and 120 kDa were clearly phosphorylated. IAS and/or forsko-
lin did not change this phosphorylation pattern in the control
platelets. Intralipid (lane 5) induced no additional tyrosine-
phosphorylated proteins, but the pp60 (src), pp68 and
pp120 were more strongly phosphorylated than in the control.
This pattern was not changed by addition of IAS (lane 6),
whereas forskolin (lanes 7 and 8) reduced the phosphorylation
of these proteins to nearly control levels. IEEC caused the
appearance of many additional, intensely tyrosine-phospho-
rylated proteins with MW about 33, 35, 38, 40 (FcQRII), 52,
55/58 (Lyn), 60 (Src), 68, 72 (Syk), 75^78 (Cortactin), 85 (PI
3-kinase, p85K), 95/97 (Vav), pp101, pp105, pp110, pp120
(GAP), pp125 (FAK) and pp140 (PLCQ). The identity of the
proteins postulated in the brackets are based on information
from Clark and Brugge [20]. IAS reduced the tyrosine protein
phosphorylation all over, but especially pp52, pp101, pp108
and pp125^130 were particularly reduced (lane 10). Forskolin
did not reduce the tyrosine protein phosphorylation to the
same degree as IAS. pp52, pp101, pp108 and pp125^130
were reduced, pp38 and pp40 were increased while the other
proteins were undisturbed (lane 11). Both IAS and forskolin
together, had an additive e¡ect on tyrosine phosphorylation
for pp72 (Syk), pp75^78, pp85 (p85K), pp101, pp105 and
pp125^130 (lane 12).
The sum of total tyrosine protein phosphorylations (TTPP)
(in percent of the total phosphorylation in control cells) ob-
tained by scanning the ¢lms for the two agonists in the pres-
ence of IAS, forskolin or both, is given in Table 1. The phos-
phorylations in the O, I, F and I/F samples were calculated as
percent of their respective control samples treated with NaCl.
IAS did not change the Intralipid-induced TTPP signi¢cantly,
suggesting that the tyrosine phosphorylations seen are due to
Intralipid itself and not caused by autocrine stimulation. For-
skolin alone and together with IAS reduced the phosphoryla-
tion to nearly control levels. IEEC-induced TTPP was reduced
by 51 þ 7% in the presence of IAS and by 42 þ 8% with for-
skolin alone, suggesting that elevation of cAMP only inhibits
responses to autocrine stimulation. When both IAS and for-
skolin were used together the TTPP was reduced by 62 þ 4%.
The IEEC response is very much the same as for what is
found with an other particle, collagen, and in sharp contrast
to the soluble agonist thrombin [12].
3.2. Polyphosphoinositides
Intralipid caused a 132% and 30% increase in the [32P]PA
and [32P]PI, respectively, but no signi¢cant changes in
[32P]PIP and [32P]PIP2 ; the increases in [32P]PI and [32P]PA
were neither altered by IAS nor forskolin, alone and in com-
bination (Table 1). This suggests that Intralipid does activate
platelets to a small extent independently of autocrine stimu-
lation and insensitive to elevation of cAMP. IEEC, on the
other hand, gave a 18-fold increase in [32P]PA (Table 1) which
is substantially greater than obtained with thrombin (0.1 U/
ml) and collagen (25 Wg/ml) under exactly the same conditions
[12]. The IEEC-induced production of [32P]PA was decreased
by 39 þ 11%, 53 þ 5% and 55 þ 7% in presence of IAS, forsko-
lin and both together, respectively. This suggests that the in-
hibition seen is completely due to inhibition of autocrine stim-
ulation and that forskolin has no e¡ect on platelet activation
induced by IEEC per se, except for inhibition of autocrine
stimulation. The production of [32P]PI, [32P]PIP and [32P]PIP2
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Table 1
Comparison between Intralipid- and IEEC-induced platelet responses with respect to their inhibition by forskolin and inhibitors of autocrine
stimulation
Response Agonist Treatment
O I F I+F
TTPP Intralipid 99 þ 9 97 þ 7 15 þ 2 17 þ 2
IEEC 996 þ 139 491 þ 67 580 þ 83 376 þ 42
PI Intralipid 130 þ 8 133 þ 20 127 þ 11 121 þ 8
IEEC 182 þ 21 158 þ 34 194 þ 40 174 þ 28
PIP Intralipid 122 þ 23 114 þ 25 104 þ 12 101 þ 10
IEEC 147 þ 8 122 þ 23 112 þ 18 102 þ 11
PIP2 Intralipid 104 þ 19 114 þ 32 115 þ 23 107 þ 13
IEEC 143 þ 21 113 þ 28 102 þ 13 97 þ 6
PA Intralipid 232 þ 27 245 þ 16 235 þ 14 230 þ 3
IEEC 1851 þ 196 1131 þ 245 866 þ 90 835 þ 120
P47 (pleckstrin) Intralipid 130 þ 9 116 þ 5 110 þ 10 109 þ 12
IEEC 533 þ 71 261 þ 44 214 þ 13 194 þ 9
DGS Intralipid 6 þ 1 5 þ 1 6 þ 4 6 þ 3
IEEC 92 þ 6 30 þ 6 16 þ 6 10 þ 3
AHS Intralipid 2 þ 0 2 þ 0 2 þ 0 2 þ 0
IEEC 24 þ 6 9 þ 1 3 þ 1 2 þ 1
GFP was treated in four di¡erent ways before stimulation with saline, Intralipid (10 mg/ml) and IEEC (10 mg I/ml). To O was added the solvent of
IAS. To I was added the IAS (RGDS, CP/CPK, SQ 29.548, cyproheptadine and BN 52021) in the concentrations described in the text to Fig. 1. To
F was added 1 WM forskolin and to I/F was added both IAS and forskolin. The GFP mixtures were incubated for 8 min at 37‡C under non-stirring
conditions with forskolin prior to addition of Intralipid or IEEC. The incubates were then stirred for 3 min before samples were taken out for
analyses. The ¢gures are given as means þ S.E. (duplicate determinations in each of three experiments) of the percentage of the control platelets
without thrombin or collagen. The ¢gures for dense granule and acid hydrolase secretion are means þ S.E. (duplicate determinations in each of
three experiments) given as percent of the maximal amount secreted. Maximal secretion is obtained from stimulation of GFP with thrombin
(5 U/ml) without IAS and forskolin. Fig. 1 shows one representative immunoblot of the total tyrosine phosphorylation.
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in IEEC-stimulated platelets showed small and insigni¢cant
di¡erences in the presence of IAS and/or forskolin.
3.3. Protein kinase C activation
Pleckstrin (P47) is abundant in platelets and the major sub-
strate for PKC [21]. Again, there were no signi¢cant di¡er-
ences in the Intralipid-induced phosphorylation of pleckstrin
alone, or in the presence of IAS and/or forskolin. IEEC pro-
duced a massive phosphorylation of pleckstrin (Table 1 and
Fig. 1, lower part) which also was greater than obtained with
thrombin and collagen [12]. The IEEC-induced phosphoryla-
tion was signi¢cantly inhibited by IAS (51 þ 8%) and forskolin
(60 þ 4%), and, as for the TTPP and [32P]PA production dis-
cussed above, we suggest that the inhibition is due to abol-
ished autocrine stimulation and the phosphorylations seen are
due to the IEEC-platelet interaction per se.
3.4. Secretion from dense granular (DGS) and lysosomes
(AHS)
Intralipid did not induce signi¢cant secretion of ADP+ATP
or acid hydrolase, and presence of IAS and/or forskolin made
no di¡erence (Table 1). However IEEC induced almost max-
imal DGS which was signi¢cantly inhibited by 67 þ 7%,
83 þ 7% and 89 þ 3%, for IAS, forskolin and both together,
respectively. The AHS secretion was only 26% of the DGS
and showed the same trends as for DGS concerning the e¡ect
of IAS and forskolin; the inhibition was 63 þ 4%, 88 þ 4% and
92 þ 4%, for IAS, forskolin and both together. In contrast to
the other responses recorded in Table 1, the secretion response
seemed to be more sensitive to forskolin. Again, there are
striking similarities with collagen [12], suggesting that the in-
hibition seen is due to autocrine inhibition, and that the re-
maining e¡ect is a pure IEEC e¡ect.
The di¡erence in platelet activation between Intralipid and
IEEC may be explained by their di¡erence in size and surface
properties. Intralipid, consisting of hydrophile liposomes with
particle diameter 6 1 Wm, might in addition to the anti-ag-
gregating hydrophilicity [22], also because of their small size
have a platelet-covering e¡ect that inhibits direct platelet-
platelet contact. IEEC is an albumin-coated particle with par-
ticle size from 1.28^3.57 Wm [2], and is because of its size
capable of activating platelets due to the recognition e¡ect
[23]. In de¢ciency of proteins, IEEC will be hydrophobic
and activate platelets [22]. This would nearly force platelets
to adhere to IEEC and give false indications of platelet acti-
vation. The albumin coat in addition to the albumin present
in Tyrode’s bu¡er should however prevent this situation.
In conclusion, the IEEC particle shows much similarities
with the particulate collagen in its activation of platelets
[12]. Both use tyrosine protein phosphorylation as an integral
part of their signal transduction mechanism which is insensi-
tive to elevated [cAMP]i. The inhibition seen in the presence
of inhibitors of autocrine stimulation, is a result of removal of
the platelets self-made activators, with the remaining activity
due to IEEC per se. These reaction mechanisms are very un-
like from those we ¢nd with thrombin as a soluble agonist
acting through G protein-mediated receptors, and might sug-
gest a common activation pathway for particulate materials in
general.
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